P2‐006: Exploratory Analyses of Cognitive Effects of Crenezumab in a Mild Alzheimer's Disease Subpopulation of a Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 2 Study (ABBY). (1st July 2016)